About Q-Linea

Company Description

Q-linea develops and delivers innovative solutions for the diagnosis of infectious diseases, with a keen focus on improving sepsis treatment while reducing antibiotic resistance

Q-linea is a company that develops innovative solutions for improved infectious disease diagnostics. The company focuses on developing instruments and consumables that benefit patients, healthcare providers and society. Q-linea develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company’s leading product, ASTar®, is a fully automated instrument for antimicrobial susceptibility testing, which produces a sensitivity profile from a positive blood culture within ~six hours. This is 24 to 40 hours faster than current diagnostics.

Year founded

2007

Served area

Worldwide

Shareholder information

Shares outstanding

29,537,947

IPO

Dec. 7, 2018

Stock exchange(s)

Nasdaq Stockholm

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.